CHMP approves NVS’ Leqvio (inclisiran) for hypercholesterolemia or mixed dyslipidemia: https://www.globenewswire.com/news-release/2020/10/16/2109800/0/en/Novartis-receives-positive-CHMP-opinion-for-Leqvio-inclisiran-a-potential-first-in-class-siRNA-for-the-treatment-of-high-cholesterol.html Rubber-stamping by the European Commission will follow in 2-3 months.